Skip to main content

Development of Effective Vaccines against Multiple Lifecycle Stages of Plasmodium vivax malaria

Objective

Plasmodium vivax is the most widespread malaria and constitutes a significant proportion of human malaria cases. P. vivax accounts for 100-400 million clinical cases each year among the 2.5 billion people living at risk in Latin America, Oceania and Asia. The recently revised Malaria Vaccine Technology Roadmap to 2030 recognises the severity of P. vivax malaria and calls for a vaccine intervention to achieve 75% efficacy over two years – equally weighted with P. falciparum. However, despite this global health need, efforts to develop interventions against this parasite have lagged far behind those for P. falciparum, in large part because of critical bottlenecks in the vaccine development process. These include i) lack of assays to prioritise and down-select new vaccines due to lack of an in vitro P. vivax long-term culture system, and ii) lack of easy access to a safe controlled human malaria infection (CHMI) model to provide an early indication of vaccine efficacy in humans. The Objectives of this MultiViVax proposal will address these critical bottlenecks and shift the “risk curve” in order to better select successful vaccine candidates against multiple lifecycle stages of P. vivax:

1. We will establish a P. vivax CHMI model in Europe for the first time to facilitate the better selection of effective vaccines and remove the current bottleneck for their early-phase clinical testing.

2. We will utilise this CHMI model to identify novel antigens associated with protective blood-stage immunity in humans by taking advantage of recent advances in immuno-screening and parasite RNASeq.

3. We will progress existing vaccines targeting the current leading antigens for both the blood- and transmission-stages along the clinical development pipeline.

4. We will develop novel transgenic parasites for use in assays in order to overcome the current bottleneck in vaccine down-selection caused by the inability to culture P. vivax parasites.

Field of science

  • /medical and health sciences/health sciences/infectious disease/malaria
  • /medical and health sciences/basic medicine/pharmacology and pharmacy/pharmaceutical drug/vaccines

Call for proposal

H2020-SC1-2016-RTD
See other projects for this call

Funding Scheme

RIA - Research and Innovation action

Coordinator

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
Address
Wellington Square University Offices
OX1 2JD Oxford
United Kingdom
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 4 526 425,25

Participants (7)

IMAXIO SA

Participation ended

France
EU contribution
€ 4 126,44
Address
Rue Saint Roch 5/7
75001 Paris
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT
France
EU contribution
€ 30 000
Address
Boulevard De Dunkerque 44 Cs 90009
13572 Marseille
Activity type
Research Organisations
THE UNIVERSITY OF EDINBURGH
United Kingdom
EU contribution
€ 30 000
Address
Old College, South Bridge
EH8 9YL Edinburgh
Activity type
Higher or Secondary Education Establishments
GENOME RESEARCH LIMITED
United Kingdom
EU contribution
€ 351 298,75
Address
The Gibbs Building, Euston Road 215
NW1 2BE London
Activity type
Research Organisations
EXPRES2ION BIOTECHNOLOGIES APS
Denmark
EU contribution
€ 25 000
Address
Agern Alle 1
2970 Horsholm
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
NOVAVAX AB
Sweden
EU contribution
€ 56 250
Address
Kungsgatan 109
753 18 Uppsala
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
OSIVAX SAS
France
EU contribution
€ 35 873,56
Address
4 Rue De Copenhague
75008 Paris
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)